You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

CLINICAL TRIALS PROFILE FOR CLARINEX D 24 HOUR


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for CLARINEX D 24 HOUR

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00636870 ↗ Fexofenadine (Allegra®) in Healthy Adults Who Have Been Identified as Slow Metabolizers for Desloratadine Completed Sanofi Phase 4 2003-02-01 To evaluate the single-dose and steady-state pharmacokinetics of desloratadine and fexofenadine in desloratadine slow metabolizers. To evaluate the safety and tolerability of desloratadine compared to fexofenadine following single and multiple oral doses administered to desloratadine slow metabolizers.
NCT00637585 ↗ Fexofenadine HCl 180 mg, Desloratadine 5 mg and Placebo in Suppression of Wheal and Flare Induced by Histamine Completed Sanofi Phase 4 2002-12-01 To examine the relative potency, onset of action and duration of action of fexofenadine HCl 180 mg (ALLEGRA) and desloratadine 5 mg (CLARINEX) as compared to placebo on skin wheals and flares induced by histamine.
NCT00757562 ↗ Safety of Desloratadine in Children With Allergy Sensitivity and Chronic Hives, Who Are Poor Metabolizers of Desloratadine (Study P02994) Completed Merck Sharp & Dohme Corp. Phase 3 2002-11-01 This study was conducted to evaluate the safety and tolerance of desloratadine after 5 weeks of repetitive dosing in children ages 2 to 12 years old with allergic hypersensitivity or chronic hives. All of the subjects enrolled in this trial were previously identified in an earlier trial to be poor metabolizers of desloratadine.
NCT00783133 ↗ Preference for Clarinex Tablets vs. Allegra Tablets in Patients With Seasonal Allergies (Study P03177) Completed Merck Sharp & Dohme Corp. Phase 4 2002-11-01 This was a crossover study designed to see if patients with seasonal allergy symptoms preferred Clarinex® or Allegra®. Patients were randomized to take 7 days of Clarinex or Allegra treatment, followed by a 5 to 28-day washout period (days when no drug is given), followed by 7 days of the opposite treatment. At the end of each 7-day treatment, patients were asked questions to determine which drug, Clarinex or Allegra, the patient prefers more.
NCT00794248 ↗ Preference for Clarinex Tablets vs. Allegra Tablets in Patients With Seasonal Allergies (Study P03179) Completed Merck Sharp & Dohme Corp. Phase 4 2002-11-01 This was a crossover study designed to see if patients with seasonal allergy symptoms preferred Clarinex® or Allegra®. Patients were randomized to take 7 days of Clarinex or Allegra treatment, followed by a 5 to 28-day washout period (days when no drug is given), followed by 7 days of the opposite treatment. At the end of each 7-day treatment, patients were asked questions to determine which drug, Clarinex or Allegra, the patient prefers more.
NCT00794495 ↗ Preference for Clarinex Tablets vs. Zyrtec Tablets in Patients With Allergies (P03181) Completed Merck Sharp & Dohme Corp. Phase 4 2002-12-01 This was a crossover study designed to see if patients with allergy symptoms preferred Clarinex® or Zyrtec®. Patients were randomized to take 7 days of Clarinex or Zyrtec treatment, followed by a 5 to 28-day washout period (days when no drug is given), followed by 7 days of the opposite treatment. At the end of each 7-day treatment, patients were asked questions to determine which drug, Clarinex or Zyrtec, the patient prefers more.
NCT00794599 ↗ Preference for Clarinex Tablets vs. Zyrtec Tablets in Patients With Allergies (P03182) Completed Merck Sharp & Dohme Corp. Phase 4 2002-12-01 This was a crossover study designed to see if patients with allergy symptoms preferred Clarinex® or Zyrtec®. Patients were randomized to take 7 days of Clarinex or Zyrtec treatment, followed by a 5 to 28-day washout period (days when no drug is given), followed by 7 days of the opposite treatment. At the end of each 7-day treatment, patients were asked questions to determine which drug, Clarinex or Zyrtec, the patient prefers more.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for CLARINEX D 24 HOUR

Condition Name

Condition Name for CLARINEX D 24 HOUR
Intervention Trials
Seasonal Allergic Rhinitis 7
Healthy 5
Perennial Allergic Rhinitis 3
Allergic Rhinitis 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for CLARINEX D 24 HOUR
Intervention Trials
Rhinitis, Allergic 9
Rhinitis 9
Rhinitis, Allergic, Seasonal 7
Rhinitis, Allergic, Perennial 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for CLARINEX D 24 HOUR

Trials by Country

Trials by Country for CLARINEX D 24 HOUR
Location Trials
United States 8
Canada 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for CLARINEX D 24 HOUR
Location Trials
Florida 5
New Jersey 2
Kentucky 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for CLARINEX D 24 HOUR

Clinical Trial Phase

Clinical Trial Phase for CLARINEX D 24 HOUR
Clinical Trial Phase Trials
Phase 4 9
Phase 3 2
Phase 2 1
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for CLARINEX D 24 HOUR
Clinical Trial Phase Trials
Completed 18
Active, not recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for CLARINEX D 24 HOUR

Sponsor Name

Sponsor Name for CLARINEX D 24 HOUR
Sponsor Trials
Merck Sharp & Dohme Corp. 9
Dr. Reddy's Laboratories Limited 6
Sanofi 2
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for CLARINEX D 24 HOUR
Sponsor Trials
Industry 19
Other 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.